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OBJECTIVES: To analyze prospectively the effect of adding Pre-
gabalin (PGB) on PRO measurements evolution in the treatment
of refractory Neck pain under routine medical practice conditions
METHODS: Post-hoc analysis of patients above 18 years, with
6-month chronic Neck pain refractory to, at least, one previous
analgesic [previous mean (SD) number of drugs was 2.1 (1.3),
22.4% on one-drug], included in a prospective, naturalistic,
12-weeks two-visit study. This analysis compared patients receiv-
ing PGB as an add-on therapy (PGB add-on) versus subjects
receiving any other analgesic pattern not including PGB (non-
PGB). PRO measurements included evaluation of severity and
interference of pain (Brief Pain Inventory), anxiety and depression
symptoms (HAD scale), and quality-of-life (SF-12). RESULTS: A
total of 312 [65.3% women, 54.2 (12.1) years] patients were
analyzed: 78.2% received PGB add-on and 21.8% non-PGB.
Twelve weeks therapy with PGB add-on was associated with
higher reduction in pain severity than in non-PGB; -3.2 (1.8) pts,
55.4% responders (350% baseline pain reduction) vs. -2.3 (2.0),
38.2% responders; p < 0.0001, respectively. Pain interference was
also reduced more with PGB add-on: -3.1 (1.9) pts vs. -2.2 (2.2),
respectively; p < 0.0001, and showed greater reduction in depres-
sion [-3.9 (4.0) pts vs. -2.4 (3.4); p < 0.0001] and anxiety [-3.6
(3.5) pts vs. -1.9 (3.2); p < 0.0001] symptoms scores, yielding to
a signiﬁcant improvement in patient’s quality of life: mental and
physical summary components changewere higher in PGB add-on
therapy group: +6.7 (10.2) vs. +3.9 (11.1); p = 0.025, and +9.1
(8.7) vs. +5.8 (7.1); p = 0.024, respectively. CONCLUSIONS:
Compared with adding other any drug, the addition of PGB to the
treatment pattern of refractory Neck pain seems to be associated
with higher improvement in PROmeasurements, including reduc-
tion of pain severity and interference and improvement of quality
of life under routine medical practice condition.
PSY48
EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN
RUSSIA: PATIENT-REPORTED DATA. INTERMEDIATE RESULTS.
PART 2
Vorobyev P1, Borisenko O2, Zhulev U3, Kopylov K4,Telnova E5,
Tonoyan A2
1Moscow Medical Academy named after I.M.Sechenov, Moscow,
Russia, 2Russian Society for Pharmacoeconomics and Outcomes
Research, Moscow, Russia, 3All-Russian Hemophilia Society, Moscow,
Russia, 4Hematological Research Center, Moscow, Russia,
5Roszdravnadzor, Moscow, Russia
OBJECTIVES: The Government of the Russian Federation
provide up to US$377 million to the management of hereditary
coagulopathies (hemophilia type A and type B, von Willebrand’s
disease) since 2008. The amount of ﬁnancing to the custom of
coagulation factors increased 20 times more for 2004–2008. At
the present time, an aggregate 3.49 IU of clotting factor VIII falls
on one citizen of Russia. Russian Society of Pharmacoeconomics
and Outcomes Research jointly with All-Russian Hemophilia
Society made the ﬁrst in Russia postal survey of all registered
Russian patients with coagulopathies for the purpose of deter-
mining epidemiology of disease, treatment modalities.
METHODS: The postal survey of 6309 patients was made in
December 2007–January 2008. This questionnaire contained
questions on factor level and presence of antibodies, the last date
determination of factor level and antibodies to it, number of
bleeding by last month, number of introductions of coagulation
factors, used medications, way of administering medications, and
a number of emergency calls, hospitalizations. The patients’ edu-
cation and employment data was also collected. RESULTS: A
total of 1030 (16.3%) completed questionnaires were received by
May 11, 2008. Forty-eight questionnaires were excluded from
analysis because of absence of the key data. A total of 520
questionnaires were analyzed, and 462 questionnaires are under
analyses now. A total of 661 (10.5%) blank questionnaires were
returned (due to death, changing place of living). Only one-third
of patients of 520 (36.5%) administer the medication with
proper frequency. The median of administration of coagulation
factors per month among patients with hemophilia was 6. The
medium frequency of emergency calling in month per patient was
equal to 0.36. The median frequency of hospitalization in month
per patient was 0.17. A total of 57.6% of patients report the
injections of medications on their own or by family members. A
total of 20.2% of patients undergo the injections in out-patient
clinics. More then 2/3 of patients use home and out-patient
treatment. Seven percent of patients receive components of
human plasma: cryoprecipitate (4.4%) and fresh frozen plasma
(3,1%). 25,6% of the patients report having virus hepatitis, 14%
of patients have problems with joint (arthrosis, arthritis, anchy-
losis and contractures). CONCLUSIONS: Intermediate results
of the survey show a very low rate of using proper prophylactic
scheme of administration of medications in patients with hemo-
philia (36.5%), in spite of presence of appropriate standards. The
rate of emergency calls and hospitalizations is comparatively
high. The majority of patients administer factors on their own or
in out-patient clinics. The rate of administration of plasma com-
ponents is still high. It increases the risk of contamination with
transmitting infections. One-quarter of patients demonstrate the
presence of serious complications: hepatitis or joints diseases.
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OBJECTIVES: Both Pregabalin (PGB) and Gabapentin (GBP) are
anti-convulsive drugs used in the ﬁrst-line therapy of Neuro-
pathic pain (NeP). Evidence of head-to-head comparison in
routine medical practice is reduced. METHODS: Post-hoc case-
control comparison from two 12-week, multicentre, naturalistic,
and prospective studies. Male and female above 18 years, refrac-
tory to previous analgesia (at least one drug), suffering chronic
pain (duration over 6 months) secondary to diabetic neuropathy,
post-herpetic or trigeminal neuralgias, cervical or lumbosacral
radiculopathies were included. Subjects were assessed at baseline
and end of the study using the SF-MPQ (pain), SDI (disability),
MOS-sleep (sleep), HADS (anxiety and depression symptoms),
and EQ-5D (health status) scales, and utilization of health care
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resources and work productivity were also recorded. RESULTS:
The sample for this analysis was composed of patients treated
with GBP (n = 44) and a random sample of 88 patients treated
with PGB and matched for age, sex, and clinical characteristics.
Mean (SD) doses for GBP and PGB were 1263 (540) and 202
(119) mg/day, respectively. Patients treated with PGB showed
greater reduction in pain intensity compared with GBP patients
(39  23 vs 28  22 mm in the VAS SF-MPQ; p = 0.008), yield-
ing to a higher signiﬁcantly proportion of patients with a 50%
reduction of baseline pain at the end of the study; 41% vs. 61%,
respectively; p = 0.029. The remaining patient-reported out-
comes improved signiﬁcantly and to a similar extent after treat-
ment with either drug. The signiﬁcantly higher drug cost of PGB
as compared with GBP was traded-off with the greater reduction
in productivity cost in the former group. CONCLUSIONS: Both
drugs were associated with a similar reduction of costs. However,
results suggest that pregabalin showed a greater effectiveness
than gabapentin in the control of NeP. These differences may
reﬂect greater difﬁculties in reaching the therapeutic dose for
gabapentin in routine medical practice.
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OBJECTIVES: One of the challenges for innovation in chronic
pain treatment is to provide consistent pain control over a 24-hour
period. How does this clinical objective translate into concepts
relevant to patients, and do the existing instruments adequately
capture these concepts? METHODS: Thirty face-to-face explor-
atory interviews were conducted by psychologists in France,
Germany and the UK with patients with chronic pain (cancer-
related pain excluded) to collect information on how they describe
the course of pain over 24 hours and how changes in pain levels
and the time they occur affects their everyday lives. In parallel, a
list of related concepts and a description of the conceptual con-
tents of existing instruments was extracted from the literature.
RESULTS: Analysis of the patient interviews resulted in the
identiﬁcation of several concepts related to 24-hour pain control
which are closely intertwined with one another: type of pain
(background, breakthrough, and end-of-dose pain), description
(occurrence, intensity, sensation), worsening, relieving, triggering
factors, impact of pain (particularly patients’ activities of daily
living, sleep andmood), pain medication (efﬁcacy, time to efﬁcacy,
duration of efﬁcacy, frequency medication is taken) and pain over
time (evolution over one day).Most of these concepts are partially
or extensively covered by existing instruments. However, no
instrument is comprehensive enough to be used as a standalone
measure. CONCLUSIONS: The control of 24-hour pain is
complex and requires multidimensional assessment. Despite the
considerable number of pain questionnaires available, no speciﬁc
measurement instrument exists that fully addresses the concerns
of patients. To accurately capture the beneﬁts of once-daily treat-
ments in pain control, researchers need either a new instrument, or
the adaptation of a series of existing questionnaires to form a
consistent and comprehensive battery.
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OBJECTIVES: To analyze prospectively the effect of adding Pre-
gabalin (PGB) on PRO measurements evolution in the treatment
of refractory Low Back Pain under routine medical practice
conditions. METHODS: Post-hoc analysis of patients above 18
years, with 6-month chronic Low Back pain refractory to, at
least, one previous analgesic [previous mean (SD) number of
drugs was 2.1 (1.3), 22.7% on one-drug], included in a prospec-
tive, naturalistic, 12-weeks two-visit study. This analysis com-
pared patients receiving PGB as an add-on therapy (PGB add-on)
versus subjects receiving any other analgesic pattern not includ-
ing PGB (non-PGB). PRO measurements included evaluation of
severity and interference of pain (Brief Pain Inventory), anxiety
and depression symptoms (HAD scale), and quality-of-life (SF-
12). RESULTS: A total of 683 [49.5% women, 55.0 (12.7) years]
patients were analyzed: 82.6% received PGB add-on and 17.4%
non-PGB. Twelve weeks therapy with PGB add-on was associ-
ated with higher reduction in pain severity than in non-PGB; -3.4
(2.0) pts, 61.6% responders (350% baseline pain reduction) vs.
-2.0 (2.1), 37.3% responders; p < 0.0001, respectively. Pain
interference was also reduced more with PGB add-on: -3.5 (2.1)
pts vs. -2.0 (2.3), respectively; p < 0.0001, and showed greater
reduction in depression [-4.0 (4.1) pts vs. -2.1 (3.3); p < 0.0001]
and anxiety [-3.7 (3.6) pts vs. -1.9 (3.0); p < 0.0001] symptoms
scores, yielding to a signiﬁcant improvement in patient’s quality
of life: mental and physical summary components change were
higher in PGB add-on therapy group: +7.3 (10.6) vs. +2.0 (7.4);
p < 0.0001, and +9.7 (9.6) vs. +5.8 (8.3); p < 0.0001, respec-
tively. CONCLUSIONS: Compared with adding other any drug,
the addition of PGB to the treatment pattern of refractory Low
Back Pain seems to be associated with higher improvement in
PRO measurements, including reduction of pain severity and
interference and improvement of quality of life under routine
medical practice condition.
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OBJECTIVES: The Government of Russian Federation provided
up to US$377 million to the management of hereditary coagulo-
pathies (hemophilia type A and type B, von Willebrand’s disease)
since 2008. The amount of ﬁnancing to the custom of coagula-
tion factors increased 20 times for 2004–2008, and at
the present, aggregate 3.49 IU of clotting factor VIII fall on one
citizen of Russia. Russian Society of Pharmacoeconomics and
Outcomes Research jointly with the All-Russian Hemophilia
Society made the ﬁrst Russian postal survey of all registered
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